Clinical trials: Human Immunodeficiency Virus Type 1
HIV Infections
Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men
The purpose of this study is to determine the safety and efficacy of a VRC DNA/rAd5 vaccine regimen in healthy, circumcised men and male-to-female (MTF) transgender persons who have sex with men.
- Trial name
- NCT00865566
- Testing
- DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine
- Where
- 22 sites in United States
- Volunteers
- 2,504 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Prevention of Infection With HIV-1
Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers
The is a blinded safety study of ibalizumab given by subcutaneous injection in sequentially increasing dose-groups of at-risk, HIV-negative, healthy volunteers.
- Trial name
- TMB-108 (NCT01292174)
- Where
- 6 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- TaiMed Biologics Inc.
Healthy
A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants
The purpose of this study is to evaluate the safety, acceptability, pharmacokinetics (what the body does to the medication), and ex vivo (tested outside the body) pharmacodynamics (what the medication does to the body) of TMC278…
- Trial name
- NCT01656018
- Testing
- TMC278, Long acting (LA)
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
HIV Infections
Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of polyvalent env (A,B,C,A/E)/gag (C) DNA and gp120 (A,B,C,A/E) protein vaccines (PDPHV201401) co-administered together with or without adjuvant…
- Trial name
- NCT04927585
- Testing
- env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Worcester HIV Vaccine
HIV Infections
Clinical Performance of Reveal G4 Rapid HIV-1 Antibody Test
To determine the efficacy of an improved rapid diagnostic test using venous whole blood and fingerstick whole blood. The clinical performance of Reveal G4 Rapid HIV-1 Antibody Test will be determined by comparing the results with…
- Trial name
- NCT02190578
- Testing
- Reveal G4
- Where
- 4 sites in United States
- Volunteers
- 1,649 people, healthy volunteers welcome
- Sponsor
- MedMira Laboratories Inc.
HIV-1, HIV Infections
Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1/2-uninfected Mothers
Objectives: Safety and immunogenicity of MVA.HIVA vaccine in 20-week-old healthy Gambian infants born to HIV-1/2-uninfected mothers.
- Trial name
- PedVacc001 (NCT00982579)
- Testing
- MVA.HIVA
- Where
- The Gambia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Medical Research Council
HIV Infections
A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells
The purpose of this study is to compare the safety, tolerability, and immunogenicity of CH505TF gp120 produced from stably transfected cells to CH505TF gp120 produced from transiently transfected cells in healthy…
- Trial name
- NCT03856996
- Testing
- Stable CH505TF gp120, Transient CH505TF gp120, Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)
- Where
- 3 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Assessing the Safety of Dapivirine Gel and Film Formulations
This is a study to determine the safety of dapivirine gel and dapvirine film for healthy, HIV-uninfected women aged 18-45 years using the product for 7 daily doses.
- Trial name
- NCT01548560
- Testing
- Dapivirine Vaginal Film, Dapivirine Vaginal Gel
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
HIV-1-infection
Longer-Acting PrEP in Transgender and Gender Diverse Texans
The long-term goal of this project is to increase uptake and adherence of LA-PrEP in TGD populations in Texas. The central hypothesis is that strategies to increase uptake of LA- PrEP that are patient centered and understand the…
- Trial name
- NCT05044286
- Testing
- no intervention
- Where
- United States
- Volunteers
- 565 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
HIV Infections
A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects
To evaluate an HIV synthetic lipopeptide candidate vaccine component, P3C541b, at two dose levels, administered subcutaneously (s.c.) in a randomized, double-blind, placebo controlled study.
- Trial name
- NCT00000845
- Testing
- P3C541b Lipopeptide
- Where
- 3 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Premature Aging
Clinical Trial to Evaluate the Addition to an Antiretroviral Treatment of a Probiotic
The main purpose of this study is to evaluate a therapy for the inflammaging (premature aging).
- Trial name
- RECOVER (NCT03542786)
- Testing
- Probiotic, Prebiotic
- Where
- Spain
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- AB Biotics, SA
HIV Infections, HIV Seronegativity
Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults
The purpose of this study is to see if the experimental vaccine, ALVAC-HIV (vCP1452) is safe and to study how the immune system responds to the vaccine.
- Trial name
- NCT00027261
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452)
- Where
- 13 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
PrEP, PrEP Adherence Monitoring
Prevention ICONA Dedicated Ensemble
Despite significant advances in HIV treatment, transmission remains a public health concern. In 2022, there were 1.3 million new HIV infections worldwide and 1,888 new diagnoses in Italy, with sexual transmission being the…
- Conditions
- PrEP, PrEP Adherence Monitoring, HIV, HIV -1 Infection
- Trial name
- PrIDE (NCT07186244)
- Where
- 53 sites in Italy
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Fondazione ICONA
Healthy
Dose Proportionality of TFV-DP After a Single Dose of GS-7340 in Women
Purpose: The purpose of this study is to characterize the dose-proportionality in the distribution of tenofovir alafenamide (TAF) and tenofovir (TFV) in plasma and mucosal tissues, and TFV-diphosphate (TFV-DP) in peripheral blood…
- Trial name
- NCT02357602
- Testing
- GS-7340
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers
To expand the available data regarding the safety and immunogenicity of 2 HIV-1 vaccine strategies: canarypox vector vCP205, or vCP205 with SF-2 rgp120.
- Trial name
- NCT00000871
- Testing
- MN rgp120/HIV-1 and GNE8 rgp120/HIV-1, MN rgp120/HIV-1 and A244 rgp120/HIV-1, ALVAC-HIV MN120TMG (vCP205)
- Where
- 18 sites in United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Study of HIV-1 Rgp-160 Administered by Mucosal Routes in Healthy Volunteers
It is probable that a mucosal approach is necessary for a prophylactic HIV vaccine protecting against sexually transmitted infection.
- Trial name
- NCT00122564
- Testing
- HIV-1 gp 160, DC-Chol
- Where
- France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV-1-infection
The Partners Scale-Up Project
An implementation project to scale-up delivery of antiretroviral-based HIV-1 prevention methods to Kenyan HIV-1 serodiscordant couples in HIV-1 care centers.
- Trial name
- NCT03052010
- Testing
- Integrated PrEP as a bridge to ART HIV-1 prevention strategy, PrEP, ART
- Where
- 2 sites in Kenya
- Volunteers
- 4,898 people, healthy volunteers welcome
- Sponsor
- University of Washington
HIV Infections
Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects
This protocol represents the second in human study of TUTI-16, and is being conducted to continue to gather safety and human immunogenicity (anti-HIV-1 Tat titers) data of subcutaneously administered TUTI-16.
- Trial name
- THYMON-10001 (NCT01144026)
- Testing
- TUTI-16 (0.2mg), TUTI-16 (1.0 mg)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Thymon, LLC
Healthy
A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants
The purpose of this study is to evaluate the single-dose pharmacokinetics and pivotal bioequivalence of Darunavir (DRV) 800 milligram (mg), Emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 10 mg when administered as a…
- Trial name
- NCT02578550
- Testing
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC), Emtricitabine/tenofovir alafenamide FDC, Darunavir
- Where
- Netherlands
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Janssen Sciences Ireland UC
HIV, Men
Reducing HIV Risk With High Risk HIV Negative Black MSM-Passport to Wellness
The proposed research study will focus on Black men who have sex with men (BMSM) who are HIV- or unknown status AND have not received HIV testing in over a year or who test irregularly (on 9/21/2016, the protocol was changed to…
- Trial name
- PtW (NCT02932384)
- Testing
- Intervention-Passport and Peer Mentor, Control-Passport Only
- Where
- 2 sites in United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Charles Drew University of Medicine and Science